MMIP Latest Update: October 2016

This is the latest update from the Medicines Manufacturing Industry Partnership. If you have any feedback on the content or information here then please email us at MMIP@bioindustry.org. If you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or sign up to our mailing list here.

This has been a busy period for the Medicines Manufacturing Industry Partnership (MMIP). Key recent activity has focused on promotion of the Fiscal Guide and the upcoming webinar to highlight how companies can make the most of the UK’s fiscal environment. The Advanced Therapies Manufacturing Taskforce is entering its final stage with a push on activity to publish an action plan before the end of the year and work has been ongoing on promoting the work of the MMIP, the Technology Roadmap on innovative technologies and the Skills Action Plan.

MMIP Fiscal Guide Summary
As part of MMIP’s work around the business environment, a guide has been published to improve understanding and clarify the current fiscal proposition for medicine manufacturing investments and activity. The summary is available as a pdf or as a powerpoint presentation and illustrates the substantial benefits already available to businesses. It highlights that a UK company which develops and manufactures here enjoy a long term effective tax rate of 11%-13% and will receive substantial tax credits along the way of up to 33p/£.

MMIP Fiscal Guide Webinar
The authors of the fiscal guide, Steve Taylor (SCI biotech) and Richard Turner (FTI consulting), will be presenting some of their findings and taking questions during a webinar on 25 October. The webinar will highlight the fiscal benefits that are available to companies in the UK. These benefits may not be widely recognised nor used effectively in companies. The authors will then be available to answer questions.

Advanced Therapies Manufacturing Taskforce
The Advanced Therapies Manufacturing Taskforce had its second meeting of three. Discussion focused on the recommendations that have been developed in workshops following the first meeting, with work continuing on potential funding streams for these recommendations. The group also spoke about how good the UK fiscal environment is compared to other countries, but that companies do not realise these benefits, this links closely to the work MMIP has been doing around the Fiscal Guide. The meeting also spoke about the need for these advanced medicines to be used in the UK in order to attract their manufacture to the UK. The successor to the former co-Chair, George Freeman MP, has been announced as Science Minister Jo Johnson MP. The Taskforce’s final meeting will be in November ahead of the publication of its Action Plan.
Kent Biogateway
Members from the MMIP Operational team attended a breakfast networking event at Kent’s Discovery Park. The event was organised in partnership with BioGateway, Kent’s professional network of life science companies, associations and institutes. It saw tenants from across the site learning about the MMIP’s progress and work with Government to represent the interests of medicines manufacturers across the country.

Funding opportunities

- **Innovate UK**
  The Knowledge Transfer Network has information highlighting the funding calls that are available from Innovate UK for advanced therapy medicinal products.

- **Medical Technologies IKC**
  Academics and researchers working in close collaboration with medical technology industry partners can apply for up to £100,000 to undertake proof of concept projects in Regenerative Medical Devices & Medical Devices with Enhanced Regenerative Functions.

- **BioIndustry Association**
  A further summary of funding opportunities is available on the BIA website.

Consultations
Here is a summary of recent and closing consultations that are of relevance to the medicines manufacturing sector. MMIP has responded to these consultations through the ABPI, BIA and KTN.

- **Innovative Medicines Initiative consultation on ATMPs**
  This consultation sought responses to help identify a portfolio of projects to be funded through IMI calls from 2017 onwards. It closed on 25 July 2016 and the outcomes of the consultation have now been published.
• **EU DH Sante consultation on the guidance on GMP for ATMPs**
  This consultation sought responses on the draft guidance before it was adopted by the Commission. It closed on 26 September 2016.

• **MHRA consultation on data integrity for GxP data**
  This consultation closes on 31 October.

• **UK Regenerative Medicines Platform consultation on challenge ideas for funding rounds**
  The [UK Regenerative Medicine Platform](#) is a UK research initiative funded by the Research Councils (MRC, BBSRC, EPSRC) to promote translational research in regenerative medicine and address the knowledge gaps and obstacles in the field. The current program ends in 2017. As they look to extend UKRMP funding, the Research Councils are seeking ‘Challenge Ideas’ and input from all interested parties.

**Upcoming activity**

- **14 October**: Navigating Regulatory Requirements for Redistributed Manufacturing in Healthcare
- **19 October**: EU Falsified Medicines Directive Briefing
- **20 October**: UK Bioscience Forum
- **25 October**: MMIP Fiscal Webinar
- **23/24 November**: 13th Annual Bioprocess UK Conference
- **30 November/1 December**: ManuPharma, Frankfurt
- **6 December**: Could the future be bright? What are the challenges & opportunities facing UK Pharma manufacturing, Milton Keynes [Details forthcoming]
- **7 December**: Cranfield University Manufacturing Symposium

I hope you find this note of interest and we will continue to communicate and create a community of committed likeminded professionals who can help with MMIP. Please contact us at MMIP@bioindustry.org or join our LinkedIn group at [http://bia.me/MMIP_LinkedIn](http://bia.me/MMIP_LinkedIn). Likewise, if you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or [sign up to our mailing list here](#).

Ian McCubbin
Chairman, Medicines Manufacturing Industry Partnership